Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHTG8P)

Drug Name

TP-0903 Drug Info

Synonyms

YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

PubChem CID: 56839178
CAS Number: CAS 1341200-45-0
TTD Drug ID: DMHTG8P

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tyrosine-protein kinase UFO (AXL)	DTT	AXL	6.677	7.261	6.33	7.021

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Chronic lymphocytic leukaemia

ICD Disease Classification

2A82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase UFO (AXL)	DTT	AXL	1.13E-65	-0.53	-2.04

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03572634) Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)